All enrolled individuals who gained at the least one dose of zosuquidar or placebo in the course of induction were being monitored for your event of adverse situations (439 patients, 219 on zosuquidar and 210 on placebo). The most typical adverse events ended up associated with the period of prolonged and substantial myelosuppression as is anticipa